5-year follow-up of patients with CLL treated in first-line with ibrutinib plus venetoclax

Chronic Lymphocytic Leukemia | Key Presentations on CLL from Recent Major ConferencesПодробнее

Time-Limited Ibrutinib Plus Venetoclax for CLL - Dr. Nitin Jain ASH 2023Подробнее

Chronic Lymphocytic Leukemia (CLL) - diagnosis, prognosis and management with IbrutinibПодробнее

Long Term Follow-Up With Ibrutinib + Venetoclax to Treat Chronic Lymphocytic LeukemiaПодробнее

Ibrutinib plus venetoclax for first-line treatment of CLL: 4-year follow-up dataПодробнее